These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

960 related items for PubMed ID: 19081397

  • 1. Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
    Yong G, Rankin J, Ferguson L, Thom J, French J, Brieger D, Chew DP, Dick R, Eccleston D, Hockings B, Walters D, Whelan A, Eikelboom JW.
    Am Heart J; 2009 Jan; 157(1):60.e1-9. PubMed ID: 19081397
    [Abstract] [Full Text] [Related]

  • 2. Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome.
    Perez de Prado A, Cuellas C, Diego A, de Miguel A, Samaniego B, Alonso-Orcajo N, Carbonell R, Pascual C, Fernandez-Vazquez F, Calabozo RG.
    Thromb Res; 2009 Dec; 124(6):678-82. PubMed ID: 19411094
    [Abstract] [Full Text] [Related]

  • 3. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial.
    Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, Slama M, Milleron O, Collet JP, Henry P, Beygui F, Drouet L, ALBION Trial Investigators.
    J Am Coll Cardiol; 2006 Sep 05; 48(5):931-8. PubMed ID: 16949482
    [Abstract] [Full Text] [Related]

  • 4. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
    Montalescot G, Sideris G, Cohen R, Meuleman C, Bal dit Sollier C, Barthélémy O, Henry P, Lim P, Beygui F, Collet JP, Marshall D, Luo J, Petitjean H, Drouet L.
    Thromb Haemost; 2010 Jan 05; 103(1):213-23. PubMed ID: 20062936
    [Abstract] [Full Text] [Related]

  • 5. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
    Buch AN, Singh S, Roy P, Javaid A, Smith KA, George CE, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R.
    Am J Cardiol; 2007 Jun 01; 99(11):1518-22. PubMed ID: 17531573
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
    Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS.
    J Am Coll Cardiol; 2006 Jan 03; 47(1):27-33. PubMed ID: 16386660
    [Abstract] [Full Text] [Related]

  • 8. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD.
    J Am Coll Cardiol; 2009 Aug 18; 54(8):678-85. PubMed ID: 19679245
    [Abstract] [Full Text] [Related]

  • 9. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E, PRINCIPLE-TIMI 44 Investigators.
    Circulation; 2007 Dec 18; 116(25):2923-32. PubMed ID: 18056526
    [Abstract] [Full Text] [Related]

  • 10. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.
    Chen WH, Lee PY, Ng W, Tse HF, Lau CP.
    J Am Coll Cardiol; 2004 Mar 17; 43(6):1122-6. PubMed ID: 15028378
    [Abstract] [Full Text] [Related]

  • 11. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L.
    Am Heart J; 2009 Apr 17; 157(4):599-605. PubMed ID: 19332184
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.
    Feldman DN, Fakorede F, Minutello RM, Bergman G, Moussa I, Wong SC.
    Am J Cardiol; 2010 Feb 01; 105(3):323-32. PubMed ID: 20102943
    [Abstract] [Full Text] [Related]

  • 14. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?
    Angiolillo DJ, Fernández-Ortiz A, Bernardo E, Barrera Ramírez C, Sabaté M, Fernandez C, Hernández-Antolín R, Escaned J, Alfonso F, Macaya C.
    J Invasive Cardiol; 2004 Apr 01; 16(4):169-74. PubMed ID: 15152138
    [Abstract] [Full Text] [Related]

  • 15. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
    Liu T, Xie Y, Zhou YJ, Li YP, Ma HY, Guo YH, Liu YY, Zhao YX, Shi DM.
    Chin Med J (Engl); 2009 Aug 05; 122(15):1732-7. PubMed ID: 19781316
    [Abstract] [Full Text] [Related]

  • 16. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
    Cuisset T, Frere C, Quilici J, Gaborit B, Castelli C, Poyet R, Bali L, Morange PE, Alessi MC, Bonnet JL.
    Am J Cardiol; 2009 Oct 15; 104(8):1078-82. PubMed ID: 19801028
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
    Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Carvajal J, Lehmann A, Lambert M, Bonnet JL, Alessi MC.
    J Am Coll Cardiol; 2006 Oct 03; 48(7):1339-45. PubMed ID: 17010792
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.